178 related articles for article (PubMed ID: 8299652)
1. Usefulness of technetium-99m hydroxymethylene diphosphonate scans in localizing bone metastases of differentiated thyroid carcinoma.
Tenenbaum F; Schlumberger M; Bonnin F; Lumbroso J; Aubert B; Benali H; Parmentier C
Eur J Nucl Med; 1993 Dec; 20(12):1168-74. PubMed ID: 8299652
[TBL] [Abstract][Full Text] [Related]
2. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
Alam MS; Takeuchi R; Kasagi K; Misaki T; Miyamoto S; Iida Y; Hidaka A; Konishi J
Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573
[TBL] [Abstract][Full Text] [Related]
3. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma.
Lind P; Gallowitsch HJ; Langsteger W; Kresnik E; Mikosch P; Gomez I
J Nucl Med; 1997 Mar; 38(3):348-52. PubMed ID: 9074515
[TBL] [Abstract][Full Text] [Related]
4. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
[TBL] [Abstract][Full Text] [Related]
5. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
6. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
7. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
[TBL] [Abstract][Full Text] [Related]
8. The value of simultaneous co-registration of 99mTc- MDP and 131Iodine in metastatic differentiated thyroid carcinoma.
Kotb MH; Omar W; El-Maghraby T; El-Bedwihy M; El-Tawdy M; Mustafa H; Al-Nahhas A
Nucl Med Rev Cent East Eur; 2007; 10(2):98-105. PubMed ID: 18228214
[TBL] [Abstract][Full Text] [Related]
9. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
10. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
Higashiyama S; Yoshida A; Kawabe J
Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma.
Kosuda S; Yokoyama H; Katayama M; Yokokawa T; Kusano S; Yamamoto O
Eur J Nucl Med; 1995 Oct; 22(10):1218-20. PubMed ID: 8542909
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
13. Potential of (99m)Tc-MIBI for detecting bone marrow metastases.
Wakasugi S; Noguti A; Katuda T; Hashizume T; Hasegawa Y
J Nucl Med; 2002 May; 43(5):596-602. PubMed ID: 11994520
[TBL] [Abstract][Full Text] [Related]
14. Use of
Wu D; Ylli D; Gomes Lima CJ; Lee W; Burman KD; Wartofsky L; Van Nostrand D
Endocrine; 2018 Oct; 62(1):57-63. PubMed ID: 29797211
[TBL] [Abstract][Full Text] [Related]
15. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
Lubin E; Mechlis-Frish S; Zatz S; Shimoni A; Segal K; Avraham A; Levy R; Feinmesser R
J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma.
Miyamoto S; Kasagi K; Misaki T; Alam MS; Konishi J
J Nucl Med; 1997 Mar; 38(3):352-6. PubMed ID: 9074516
[TBL] [Abstract][Full Text] [Related]
18. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
19. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
[TBL] [Abstract][Full Text] [Related]
20. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer?
Fatourechi V; Hay ID; Mullan BP; Wiseman GA; Eghbali-Fatourechi GZ; Thorson LM; Gorman CA
Thyroid; 2000 Jul; 10(7):573-7. PubMed ID: 10958309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
